SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing a significant rally following a CMS announcement that finalizes 2027 Medicare Advantage payment rates at a higher-than-expected increase, alleviating major industry uncertainty. The community is actively debating the sustainability of these gains, with many investors viewing the news as a long-awaited relief catalyst while others remain cautious of ongoing sector volatility and regulatory headwinds.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing significant volatility and downward pressure following a recent reverse stock split, sparking intense debate among community members who are split between betting on a potential short squeeze and warning of further downside. Traders are actively monitoring management's silence on guidance and the stock's proximity to pre-split lows, with many users expressing frustration over long-term performance while others hunt for technical entry points.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is currently seeing intense debate among investors as the stock faces downward pressure, with bears highlighting concerns over certification timelines, testing delays, and competitive challenges in the eVTOL space. Meanwhile, bulls continue to emphasize the company's long-term potential, citing strategic partnerships and upcoming operational milestones as catalysts that could drive a significant recovery.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense community debate as investors weigh ongoing price volatility and bearish sentiment against its institutional adoption, including new tokenization pilots and enterprise integrations. While some users are frustrated by its recent market performance compared to broader crypto trends, others view the current price levels as a long-term accumulation opportunity driven by potential regulatory clarity and continued RWA infrastructure development.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing significant downward pressure following the release of Phase 3 clinical trial data for its thyroid eye disease candidate, elegrobart, which investors deemed underwhelming compared to Amgen's established Tepezza. While some analysts maintain a bullish long-term outlook citing potential differentiation in dosing and subcutaneous delivery, the market is currently reacting with heavy put-option hedging and skepticism regarding the treatment's competitive profile.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors weigh recent reports of its custom TPU chip developments and expanded AI compute partnerships with Anthropic against broader sector volatility. The community remains focused on the company's long-term infrastructure strategy, debating whether these AI-driven efficiency gains represent a fundamental shift in the chip demand landscape.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing significant downward pressure as investors react to a debt offering, raising concerns over the company's financial leverage and capital management. Meanwhile, the community remains deeply divided, with some traders betting on further downside due to fundamental weaknesses while others identify the sharp sell-off as a potential deep-value opportunity.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

Investors are closely monitoring a structural rotation out of mega-cap tech, with many questioning if the long-running momentum behind these dominant names is finally stalling. While some market participants express concerns over stretched AI valuations and cooling institutional sentiment, others remain focused on the potential for broader market participation as the Magnificent Seven face increased scrutiny and technical resistance.

Taseko Mines Ltd. operates as a mining company which engages in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.

Taseko Mines Ltd.

Taseko Mines is trending as investors bet on the companys transition into a major U.S. copper producer, with the Florence Copper project nearing commercial production and poised to double output. The community is actively discussing the potential for a structural copper supply shortage, the strategic importance of North American assets for AI and green energy, and the stock's significant upside potential as it moves toward operational milestones.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Market sentiment remains volatile as investors closely monitor a looming Tuesday deadline for a potential Iran ceasefire, with many traders anticipating a 'Taco Tuesday' scenario of further extensions rather than immediate resolution. Community discussions are heavily fixated on the ongoing Strait of Hormuz tensions, high oil prices, and accusations of market manipulation by institutional players to sustain price levels despite broader geopolitical uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock.</li><li>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company announced an agreement with a major global pharmaceutical company.</li><li>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.</li></ul>U.S. equities were in the green in Tuesday’s pre-market trade after President Donald Trump reportedly indicated that he would be willing to end the Iran war without a complete reopening of the Strait of Hormuz.According to a report by The Wall Street Journal, President Trump told his aides about his willingness to end the war without getting Iran to reopen the strait following an assessment that this mission would result in prolonging the conflict beyond the four to six-week timeline.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.92%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.86%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.94%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences Inc. (ARTL)</a>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock. Artelo stated that it intends to use the proceeds to repay a bridge debt and meet working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 139% year-to-date.<a href="https://stocktwits.com/symbol/BFRG">Bullfrog AI Holdings Inc. (BFRG)</a>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bfrg-stock-more-than-doubled-today-what-is-fueling-the-surge/cZERFnXRIZz">announced</a> an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.<a href="https://stocktwits.com/symbol/BFRG">BFRG stock</a> is up 19% year-to-date.<a href="https://stocktwits.com/symbol/HKIT">Hitek Global Inc. (HKIT)</a>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.<a href="https://stocktwits.com/symbol/HKIT">HKIT stock</a> is down 98% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-fed-iran-war-effects-not-facing-policy-decision-yet/cZERs6iRIN9">Powell Says Fed ‘Not Really Facing’ Policy Decision Yet Amid Iran Oil Shock – Adds Central Bank Will Be ‘Mindful Of The Broader Context’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Equity

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences Targets GLP-1 Boom with Muscle Preservation Strategy as Stock Eyes Squeeze Potential

Artelo Biosciences (NASDAQ:ARTL) is expanding the development pathway for its lead candidate ART27.13, positioning the compound as a potential companion therapy to GLP-1 weight-loss drugs, one of the fastest-growing segments in biopharma.

<ul><li>Artelo indicated it will defer the planned securities offering for the moment.</li><li>The company confirmed no shares were sold and may consider fundraising later.</li><li>On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.</li></ul>Artelo Biosciences, Inc. (ARTL)&nbsp; has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.<h2 class="st-heading-2">Artelo Pauses Proposed Securities Offering</h2>Artelo stated that it does not plan to move forward with the proposed securities offering at this time.&nbsp;The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences stock</a> traded over 420% higher on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;Additionally, the company announced a new private placement involving the sale of more than 3.18 million shares or equivalent pre-funded warrants. The transaction is expected to finalize around March 30, and the company expects gross proceeds of approximately $11 million.<h2 class="st-heading-2">Strategic Expansion Initiative</h2>On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.&nbsp;The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.ARTL stock has gained over 170% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/entergy-meta-ink-agreement-to-fund-new-gas-plants-for-louisiana-ai-data-center/cZ3H5r4RImT">Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

 Why Did ARTL Stock Skyrocket Over 420% Today? 

Artelo requested withdrawal of its Form S-1, effective March 25, and will not proceed with the planned securities offering.

Small Cap Stocks To Watch Now - March 18th

AltC Acquisition, Direxion Daily MU Bull 2X Shares, and Artelo Biosciences are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of...

Nano-Cap Artelo Biosciences Stock Explodes Glaucoma Study Collaboration Ignites Rally

Artelo Biosciences shares jump after a glaucoma study deal to test ART27.13, a new treatment targeting eye pressure in patients.read more...

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul><li>Artelo is developing ART27.13, which is a synthetic drug that targets cannabinoid receptors, but only outside the brain.</li><li>The company said preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow.</li><li>Artelo is developing ART27.13 as a once-daily oral drug that could improve body weight, appetite, muscle degeneration, and overall quality of life in cancer patients.</li></ul>&nbsp;Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&amp;D Division.The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences shares</a> were up more than 33% in Wednesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.—What Is The ART27.13 Treatment?ART27.13 is a synthetic drug that targets cannabinoid receptors, but only outside the brain. The company stated that preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow. These are the two key mechanisms involved in intraocular pressure regulation.“The ophthalmology community has long recognized the potential of cannabinoids in managing intraocular pressure, but their use has been limited by central nervous system effects. ART27.13’s peripherally selective design may overcome this challenge,” said Artelo CEO Greg D. Gorgas.The company is developing ART27.13 as a once-daily, orally administered drug. Artelo says it has the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients.What Does Artelo Do?Artelo is a California-based clinical-stage pharmaceutical company currently developing and commercializing proprietary therapeutics that modulate how fat-based molecules signal between cells.The company has a diversified pipeline of therapeutics for patients with anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 75% year-to-date, but down 61% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 18% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palladyne-ai-subsidiary-wins-us-navy-contract-for-near-hypersonic-missiles/cZ379ezRIgL">Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ARTL Stock Soaring Today?

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ARTL News

ARTLArtelo Biosciences Inc